These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 31038768)

  • 1. Safety profile of ultrasound enhancing agents in echocardiography.
    Kumar S; Purtell C; Peterson A; Gibbons P; Khan AM; Heitner SB
    Echocardiography; 2019 Jun; 36(6):1041-1044. PubMed ID: 31038768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of Severe Adverse Drug Reactions to Ultrasound Enhancement Agents in a Contemporary Echocardiography Practice.
    Ali MT; Johnson M; Irwin T; Henry S; Sugeng L; Kansal S; Allison TG; Bremer ML; Jones VR; Martineau MD; Wong C; Marecki G; Stebbins J; Michelena HI; McCully RB; Svatikova A; Padang R; Scott CG; Kanuga MJ; Arsanjani R; Pellikka PA; Kane GC; Thaden JJ
    J Am Soc Echocardiogr; 2024 Mar; 37(3):276-284.e3. PubMed ID: 37879379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety of deFinity and Optison for ultrasound image enhancement: a retrospective analysis of 78,383 administered contrast doses.
    Wei K; Mulvagh SL; Carson L; Davidoff R; Gabriel R; Grimm RA; Wilson S; Fane L; Herzog CA; Zoghbi WA; Taylor R; Farrar M; Chaudhry FA; Porter TR; Irani W; Lang RM
    J Am Soc Echocardiogr; 2008 Nov; 21(11):1202-6. PubMed ID: 18848430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety With Echocardiographic Contrast Agents.
    Muskula PR; Main ML
    Circ Cardiovasc Imaging; 2017 Apr; 10(4):. PubMed ID: 28377467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute mortality in hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent: results in 18,671 consecutive studies.
    Kusnetzky LL; Khalid A; Khumri TM; Moe TG; Jones PG; Main ML
    J Am Coll Cardiol; 2008 Apr; 51(17):1704-6. PubMed ID: 18436124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of Definity on systemic and pulmonary hemodynamics in patients.
    Wei K; Main ML; Lang RM; Klein A; Angeli S; Panetta C; Mikati I; Lee LV; Bernstein JA; Ahmad M
    J Am Soc Echocardiogr; 2012 May; 25(5):584-8. PubMed ID: 22365709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics and Echogenicity of Clinical Ultrasound Contrast Agents: An In Vitro and In Vivo Comparison Study.
    Hyvelin JM; Gaud E; Costa M; Helbert A; Bussat P; Bettinger T; Frinking P
    J Ultrasound Med; 2017 May; 36(5):941-953. PubMed ID: 28240842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultrasound contrast agents: balancing safety versus efficacy.
    Main ML; Goldman JH; Grayburn PA
    Expert Opin Drug Saf; 2009 Jan; 8(1):49-56. PubMed ID: 19236217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of ultrasound contrast agents in patients with known or suspected cardiac shunts.
    Parker JM; Weller MW; Feinstein LM; Adams RJ; Main ML; Grayburn PA; Cosgrove DO; Goldberg BA; Darge K; Nihoyannopoulos P; Wilson S; Monaghan M; Piscaglia F; Fowlkes B; Mathias W; Moriyasu F; Chammas MC; Greenbaum L; Feinstein SB
    Am J Cardiol; 2013 Oct; 112(7):1039-45. PubMed ID: 23816393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of myocardial contrast echocardiography on vascular permeability: comparison of three different contrast agents.
    Li P; Armstrong WF; Miller DL
    Ultrasound Med Biol; 2004 Jan; 30(1):83-91. PubMed ID: 14962612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased Susceptibility for Adverse Reactions to Ultrasound Enhancing Agents in Sickle Cell Disease.
    Wu M; Fields JJ; Sachdev V; Belcik JT; Chen J; Reed F; Fu X; Hodovan J; Harmann LM; Swistara G; Lindner JR
    J Am Soc Echocardiogr; 2023 Feb; 36(2):208-215. PubMed ID: 36113741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of ultrasound contrast agents in current clinical practice with special focus on DEFINITY
    Salih M; Ali SM; Jena N; Ananthasubramaniam K
    Future Cardiol; 2021 Mar; 17(2):197-214. PubMed ID: 32897099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CaRES (Contrast Echocardiography Registry for Safety Surveillance): a prospective multicenter study to evaluate the safety of the ultrasound contrast agent definity in clinical practice.
    Weiss RJ; Ahmad M; Villanueva F; Schmitz S; Bhat G; Hibberd MG; Main ML;
    J Am Soc Echocardiogr; 2012 Jul; 25(7):790-5. PubMed ID: 22560734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of ultrasound pulses combined with Definity for targeted blood-brain barrier disruption: a feasibility study.
    McDannold N; Vykhodtseva N; Hynynen K
    Ultrasound Med Biol; 2007 Apr; 33(4):584-90. PubMed ID: 17337109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Case Report of Cardiac Arrest After Intravenous Administration of Sulfur Hexafluoride (Lumason
    Arnouk S; Huynh Q; Saric M; Papadopoulos J
    J Pharm Pract; 2024 Apr; 37(2):509-512. PubMed ID: 36803045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perflutren-based echocardiographic contrast in patients with right-to-left intracardiac shunts.
    Kalra A; Shroff GR; Erlien D; Gilbertson DT; Herzog CA
    JACC Cardiovasc Imaging; 2014 Feb; 7(2):206-7. PubMed ID: 24524748
    [No Abstract]   [Full Text] [Related]  

  • 17. Echo contrast-enhanced diagnosis of atrial septal defect.
    Rosenzweig BP; Nayar AC; Varkey MP; Kronzon I
    J Am Soc Echocardiogr; 2001 Feb; 14(2):155-7. PubMed ID: 11174451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of contrast agent use during stress echocardiography in patients with elevated right ventricular systolic pressure: a cohort study.
    Abdelmoneim SS; Bernier M; Scott CG; Dhoble A; Ness SA; Hagen ME; Moir S; McCully RB; Pellikka PA; Mulvagh SL
    Circ Cardiovasc Imaging; 2010 May; 3(3):240-8. PubMed ID: 20233859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of Ultrasound Contrast Agents in Pediatric Patients With Sickle Cell Disease and Trait.
    Ntoulia A; Darge K; Thompson AA; Back SJ
    J Ultrasound Med; 2024 Jan; 43(1):189-200. PubMed ID: 37929626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved left ventricular endocardial border delineation and opacification with OPTISON (FS069), a new echocardiographic contrast agent. Results of a phase III Multicenter Trial.
    Cohen JL; Cheirif J; Segar DS; Gillam LD; Gottdiener JS; Hausnerova E; Bruns DE
    J Am Coll Cardiol; 1998 Sep; 32(3):746-52. PubMed ID: 9741522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.